Simpson Thacher represented the underwriters in an SEC registered offering by AstraZeneca Finance LLC, and guaranteed by AstraZeneca PLC, of $2 billion of fixed rate notes with maturities ranging between five and ten years, which closed on March 2, 2026.
AstraZeneca is a global, science-led, patient-focused pharmaceutical company, committed to excellence in the research, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: (i) Oncology, (ii) BioPharmaceuticals (primarily comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and (iii) Rare Disease. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide.
The Simpson Thacher team included Mark Brod, Adriana Estor-Restrepo and Deane Ciampa (Capital Markets); Jonathan Cantor and Benjamin Bressler (Tax); Vanessa Burrows and Jacob Madden (Healthcare); Christine Song (IP); and Jennie Getsin (FINRA and Blue Sky).